vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and RE/MAX Holdings, Inc. (RMAX). Click either name above to swap in a different company.
RE/MAX Holdings, Inc. is the larger business by last-quarter revenue ($71.1M vs $44.9M, roughly 1.6× AbCellera Biologics Inc.). RE/MAX Holdings, Inc. runs the higher net margin — 2.0% vs -19.9%, a 22.0% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs -1.8%). RE/MAX Holdings, Inc. produced more free cash flow last quarter ($33.5M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs -4.7%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.
ABCL vs RMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $71.1M |
| Net Profit | $-8.9M | $1.4M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | 13.1% |
| Net Margin | -19.9% | 2.0% |
| Revenue YoY | 788.4% | -1.8% |
| Net Profit YoY | 73.9% | -75.2% |
| EPS (diluted) | $-0.03 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $71.1M | ||
| Q3 25 | $9.0M | $73.2M | ||
| Q2 25 | $17.1M | $72.8M | ||
| Q1 25 | $4.2M | $74.5M | ||
| Q4 24 | $5.0M | $72.5M | ||
| Q3 24 | $6.5M | $78.5M | ||
| Q2 24 | $7.3M | $78.5M | ||
| Q1 24 | $10.0M | $78.3M |
| Q4 25 | $-8.9M | $1.4M | ||
| Q3 25 | $-57.1M | $4.0M | ||
| Q2 25 | $-34.7M | $4.7M | ||
| Q1 25 | $-45.6M | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $-51.1M | $966.0K | ||
| Q2 24 | $-36.9M | $3.7M | ||
| Q1 24 | $-40.6M | $-3.4M |
| Q4 25 | -63.7% | 13.1% | ||
| Q3 25 | -851.8% | 25.0% | ||
| Q2 25 | -290.2% | 19.3% | ||
| Q1 25 | -1479.6% | 7.2% | ||
| Q4 24 | — | 5.9% | ||
| Q3 24 | -1439.4% | 19.4% | ||
| Q2 24 | -1276.2% | 20.6% | ||
| Q1 24 | -551.5% | 5.8% |
| Q4 25 | -19.9% | 2.0% | ||
| Q3 25 | -637.8% | 5.4% | ||
| Q2 25 | -203.3% | 6.4% | ||
| Q1 25 | -1077.2% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | -785.4% | 1.2% | ||
| Q2 24 | -504.3% | 4.7% | ||
| Q1 24 | -408.0% | -4.3% |
| Q4 25 | $-0.03 | — | ||
| Q3 25 | $-0.19 | — | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.14 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $118.7M |
| Total DebtLower is stronger | — | $432.2M |
| Stockholders' EquityBook value | $966.9M | $452.4M |
| Total Assets | $1.4B | $582.5M |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | $118.7M | ||
| Q3 25 | $83.2M | $107.5M | ||
| Q2 25 | $92.4M | $94.3M | ||
| Q1 25 | $159.3M | $89.1M | ||
| Q4 24 | $156.3M | $96.6M | ||
| Q3 24 | $126.6M | $83.8M | ||
| Q2 24 | $148.3M | $66.1M | ||
| Q1 24 | $123.6M | $82.1M |
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
| Q4 25 | $966.9M | $452.4M | ||
| Q3 25 | $964.0M | $448.1M | ||
| Q2 25 | $1.0B | $442.4M | ||
| Q1 25 | $1.0B | $433.5M | ||
| Q4 24 | $1.1B | $429.5M | ||
| Q3 24 | $1.1B | $423.1M | ||
| Q2 24 | $1.1B | $418.4M | ||
| Q1 24 | $1.1B | $412.0M |
| Q4 25 | $1.4B | $582.5M | ||
| Q3 25 | $1.4B | $582.2M | ||
| Q2 25 | $1.4B | $574.8M | ||
| Q1 25 | $1.3B | $571.4M | ||
| Q4 24 | $1.4B | $581.6M | ||
| Q3 24 | $1.4B | $578.6M | ||
| Q2 24 | $1.4B | $571.4M | ||
| Q1 24 | $1.5B | $566.7M |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $40.9M |
| Free Cash FlowOCF − Capex | $-44.6M | $33.5M |
| FCF MarginFCF / Revenue | -99.4% | 47.1% |
| Capex IntensityCapex / Revenue | 21.9% | 10.4% |
| Cash ConversionOCF / Net Profit | — | 28.39× |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $56.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $40.9M | ||
| Q3 25 | $-52.6M | $17.7M | ||
| Q2 25 | $-32.4M | $4.6M | ||
| Q1 25 | $-11.6M | $5.7M | ||
| Q4 24 | $-108.6M | $59.7M | ||
| Q3 24 | $-28.9M | $17.6M | ||
| Q2 24 | $-30.0M | $15.9M | ||
| Q1 24 | $-41.7M | $9.4M |
| Q4 25 | $-44.6M | $33.5M | ||
| Q3 25 | $-61.5M | $16.4M | ||
| Q2 25 | $-45.8M | $2.9M | ||
| Q1 25 | $-22.2M | $4.0M | ||
| Q4 24 | $-187.0M | $53.0M | ||
| Q3 24 | $-47.4M | $16.3M | ||
| Q2 24 | $-50.1M | $14.0M | ||
| Q1 24 | $-65.8M | $6.8M |
| Q4 25 | -99.4% | 47.1% | ||
| Q3 25 | -687.0% | 22.4% | ||
| Q2 25 | -267.9% | 4.0% | ||
| Q1 25 | -524.0% | 5.3% | ||
| Q4 24 | -3702.8% | 73.2% | ||
| Q3 24 | -728.4% | 20.8% | ||
| Q2 24 | -683.8% | 17.8% | ||
| Q1 24 | -661.5% | 8.6% |
| Q4 25 | 21.9% | 10.4% | ||
| Q3 25 | 99.7% | 1.8% | ||
| Q2 25 | 78.2% | 2.2% | ||
| Q1 25 | 251.1% | 2.3% | ||
| Q4 24 | 1552.7% | 9.1% | ||
| Q3 24 | 284.6% | 1.7% | ||
| Q2 24 | 274.6% | 2.4% | ||
| Q1 24 | 242.5% | 3.3% |
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCL
Segment breakdown not available.
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
